This approach is already under investigation for a combination of the anti-ErbB2 Trastuzumab and anti-PD1 Pembrolizumab8, and could be further adopted in the future considering that some immunomodulatory antibodies have already been used in clinical trials for the therapy of breast cancer showing safety and efficacy8,16,17. This evidence concerns the gene ERBB2 and breast carcinoma.